Internal Medicine, Nephrology · Fremont, CA
NPI
1609067537
Since 2007
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1999 Mowry Ave, Suite R
Fremont, CA, 94538
Phone (510) 745-8187
Groups this clinician bills Medicare through
Medicare paid, 2024
$258K
2,510 services
Medicare patients, 2024
492
Average age 76
Drug cost, 2024
$827K
1,992 prescriptions
Company payments, 2025
$22K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Varun Chawla was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 563 times for 231 patients. In total Varun Chawla billed 2,510 services in 29 codes, and Medicare paid $258K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-09-12.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 563 | 231 | $14.30 | $8,050 |
| 99214 Office E&M - Established | Office | 473 | 209 | $105.96 | $50K |
| 99232 Hospital E&M - Subsequent | Facility | 269 | 143 | $68.55 | $18K |
| 90960 ESRD Related Services (not dialysis) | Office | 229 | 32 | $310.23 | $71K |
| 99233 Hospital E&M - Subsequent | Facility | 221 | 106 | $104.19 | $23K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 132 | 32 | $59.20 | $7,814 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 86 | 32 | $46.00 | $3,956 |
| 99443 Telephone Services | Office | 80 | 54 | $113.68 | $9,095 |
| 99223 Hospital E&M - Initial | Facility | 75 | 72 | $148.99 | $11K |
| 99215 Office E&M - Established | Office | 72 | 46 | $167.42 | $12K |
| 90935 Hemodialysis | Facility | 46 | 33 | $62.54 | $2,877 |
| 99204 Office E&M - New | Office | 31 | 31 | $139.39 | $4,321 |
| 96372 Injection Administration | Office | 30 | 12 | $12.74 | $382 |
| 99222 Hospital E&M - Initial | Facility | 19 | 19 | $114.13 | $2,168 |
| 99497 Care Management/Coordination | Facility | 11 | 11 | $67.45 | $742 |
By year: 2022 $202K for 1,767 services; 2023 $223K for 1,734 services; 2024 $258K for 2,510 services.
Medicare prescription drug claims, 2024
In 2024, the drug Varun Chawla prescribed most often to Medicare patients was Calcitriol, with 365 prescriptions and refills. In total Varun Chawla wrote 1,992 Medicare prescriptions that cost $827K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Calcitriol Generic | 365 | 1,018 | 109 | $7,436 |
| Farxiga Dapagliflozin Propanediol | 177 | 417 | 54 | $214K |
| Lokelma Sodium Zirconium Cyclosilicate | 146 | 259 | 37 | $195K |
| Losartan Potassium Generic | 131 | 393 | 46 | $1,197 |
| Amlodipine Besylate Generic | 105 | 312 | 39 | $555 |
| Carvedilol Generic | 103 | 240 | 26 | $705 |
| Hydralazine Hcl Generic | 94 | 238 | 33 | $1,161 |
| Sevelamer Carbonate Generic | 72 | 139 | 23 | $26K |
| Rayaldee Calcifediol | 54 | 54 | 20 | $67K |
| Calcium Acetate Generic | 49 | 88 | 15 | $4,627 |
| Kerendia Finerenone | 49 | 106 | 15 | $66K |
| Furosemide Generic | 47 | 133 | 15 | $480 |
| Allopurinol Generic | 43 | 119 | 13 | $479 |
| Xphozah Tenapanor Hcl | 29 | 30 | Under 11 | $85K |
| Lisinopril Generic | 29 | 59 | Under 11 | $104 |
Brand drugs: - claims; generic drugs: 1,421 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Varun Chawla $22K ($22K in general payments such as food, travel and fees) from 25 companies. The largest payer was Novartis Pharmaceuticals Corporation with $8,251.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 13 | $8,251 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. 4578.T | 16 | $6,818 |
| Calliditas Therapeutics US Inc. | 7 | $4,238 |
| Travere Therapeutics, Inc. TVTX | 7 | $879 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $284 |
| Amgen Inc. AMGN | 12 | $259 |
| Mallinckrodt Hospital Products Inc. | 8 | $187 |
| Fresenius USA Marketing, Inc. | 9 | $184 |
| Novo Nordisk Inc NVO | 6 | $113 |
| OPKO Pharmaceuticals, LLC | 6 | $106 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.